Translate page

Francisco Cervantes, MD, PhDPhoto Cervantes 1

Hematology Department

Hospital Clínic

University of Barcelona

Barcelona, Spain

 

Dr Francisco Cervantes is senior consultant at the Hematology Department of the Hospital Clínic of Barcelona and professor at the University of Barcelona. His scientific interest has been focused on the study of chronic myeloid leukemia (CML) and the Ph-negative chronic myeloproliferative neoplasms (MPNs), mainly their natural history, prognosis, biology, and treatment. As a result of the activity in this field, he has published over 300 articles in peer-review journals. He was coauthor of the publications of the IRIS study that allowed the approval of imatinib as frontline treatment of CML, participated in the introduction of the second-generation tyrosine kinase inhibitors, and is a member of the expert panels of the European LeukemiaNet for CML and MPN treatment. In the MPN field, he was the leading author of the prognostic classification of primary myelofibrosis or IPSS. Dr Cervantes is a member of the American Society of Hematology, the European Hematology Association, the International Working Group for MPN Research and Treatment, the European LeukemiaNet, and the PETHEMA Spanish Collaborative Group.